Chai Discovery closed a $130 million Series B to expand its AI‑driven de novo antibody design platform, Chai‑2. The company reported double‑digit success rates in zero‑shot antibody design benchmarks and said it can progress from in‑silico design to wet‑lab validation in under two weeks. Chai’s investors are backing efforts to scale computational design into therapeutics discovery, with the company claiming strong developability profiles across designed full‑length monoclonal antibodies. The financing will fund R&D, productization of the design suite and commercialization efforts. The raise underscores investor appetite for AI platforms that promise faster hit‑finding and higher experimental success rates; pharmaceutical partners and buyers will evaluate whether Chai’s models generalize across challenging targets and translate into clinic‑ready candidates.